BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

504 related articles for article (PubMed ID: 3489128)

  • 1. Acute and chronic polyarthritis induced by an aqueous form of 6-O-acyl and N-acyl derivatives of N-acetylmuramyl-L-alanyl-D-isoglutamine in euthymic rats and athymic nude rats.
    Kohashi O; Kohashi Y; Shigematsu N; Ozawa A; Kotani S
    Lab Invest; 1986 Sep; 55(3):337-46. PubMed ID: 3489128
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New model of a synthetic adjuvant, N-acetylmuramyl-L-alanyl-D-isoglutamine- induced arthritis: clinical and histologic studies in athymic nude and euthymic rats.
    Kohashi O; Aihara K; Ozawa A; Kotani S; Azuma I
    Lab Invest; 1982 Jul; 47(1):27-36. PubMed ID: 7087395
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhancement of serum antibody production in mice by oral administration of lipophilic derivatives of muramylpeptides and bacterial lipopolysaccharides with bovine serum albumin.
    Ogawa T; Kotani S; Shimauchi H
    Methods Find Exp Clin Pharmacol; 1986 Jan; 8(1):19-26. PubMed ID: 3702542
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhancement of serum antibody production in mice by oral administration of lipophilic derivatives of muramyl peptides and bacterial lipopolysaccharides with bovine serum albumin.
    Ogawa T; Kotani S; Shimauchi H
    Methods Find Exp Clin Pharmacol; 1986 Feb; 8(2):117-25. PubMed ID: 3713372
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adjuvant polyarthritis. V. Induction by N-acetylmuramyl-L-alanyl-D-isoglutamine, the smallest peptide subunit of bacterial peptidoglycan.
    Chang YH; Pearson CM; Chedid L
    J Exp Med; 1981 Apr; 153(4):1021-6. PubMed ID: 6972989
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Local tolerance of muroctasin injection in rabbits.
    Nakashima K; Jindo T; Nomura M
    Arzneimittelforschung; 1988 Jul; 38(7A):1038-9. PubMed ID: 3190798
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antigenicity study of muroctasin.
    Yamaguchi F; Hattori H; Wagai N; Tsukada W
    Arzneimittelforschung; 1988 Jul; 38(7A):1034-7. PubMed ID: 3190797
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Specific binding sites of muroctasin on murine macrophages.
    Akasaki M; Masayasu H; Tsukada W; Takegoshi T
    Arzneimittelforschung; 1988 Jul; 38(7A):978-80. PubMed ID: 3190804
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stimulation of non-specific resistance to infection by muroctasin.
    Otani T; Une T; Osada Y
    Arzneimittelforschung; 1988 Jul; 38(7A):969-76. PubMed ID: 3056426
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutagenicity studies of muroctasin.
    Shimada H; Hattori C; Sato T
    Arzneimittelforschung; 1988 Jul; 38(7A):1031-3. PubMed ID: 3056424
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel immunostimulator, N-[alpha-O-benzyl-N-(acetylmuramyl)-L-alanyl-D-isoglutaminyl]-N6-trans-(m-nitrocinnamoyl)-L-lysine, and its adjuvancy on the hepatitis B surface antigen.
    Yang HZ; Xu S; Liao XY; Zhang SD; Liang ZL; Liu BH; Bai JY; Jiang C; Ding J; Cheng GF; Liu G
    J Med Chem; 2005 Aug; 48(16):5112-22. PubMed ID: 16078831
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acute toxicity of muroctasin in mice, rats and dogs.
    Ono Y; Iwasaki T; Furuhama K; Onodera T
    Arzneimittelforschung; 1988 Jul; 38(7A):1022-4. PubMed ID: 3190794
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metabolic disposition of 14C-muroctasin in laboratory animals.
    Ono K; Masayasu H; Hashimoto F; Yamada M; Takegoshi T
    Arzneimittelforschung; 1988 Jul; 38(7A):1009-14. PubMed ID: 3190792
    [TBL] [Abstract][Full Text] [Related]  

  • 14. General pharmacological properties of muroctasin.
    Kojima H; Hirohashi M; Kasai Y; Takasuna K; Fukumoto C; Akashi A
    Arzneimittelforschung; 1988 Jul; 38(7A):1002-9. PubMed ID: 3190791
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Arthritis-inducing ability of a synthetic adjuvant, N-acetylmuramyl peptides, and bacterial disaccharide peptides related to different oil vehicles and their composition.
    Kohashi O; Tanaka A; Kotani S; Shiba T; Kusumoto S; Yokogawa K; Kawata S; Ozawa A
    Infect Immun; 1980 Jul; 29(1):70-5. PubMed ID: 7399708
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biotransformation of muroctasin in mice.
    Matsubayashi K; Takegoshi T
    Arzneimittelforschung; 1988 Jul; 38(7A):1015-8. PubMed ID: 3190793
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chronic toxicity of muroctasin in mice.
    Ono Y; Sekiguchi M; Aihara K; Onodera T
    Arzneimittelforschung; 1988 Jul; 38(7A):1028-30. PubMed ID: 3190796
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of muroctasin on the activities of drug metabolizing enzymes in liver microsomes of rats.
    Kamataki T; Komori M; Iwasaki M; Ohi H; Kitada M; Miura T; Ono K
    Arzneimittelforschung; 1988 Jul; 38(7A):1019-22. PubMed ID: 3263867
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Studies on the stability of muroctasin and degradation products built under extreme conditions.
    Moroi R; Yamazaki K; Hirota T; Watanabe S; Oki M; Toriyama M; Ichinohe A; Kataoka K
    Arzneimittelforschung; 1988 Jul; 38(7A):959-68. PubMed ID: 3190803
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synergistic generation of tumoricidal macrophages by muroctasin and interferon-gamma.
    Nagao S; Sato K; Osada Y
    Arzneimittelforschung; 1988 Jul; 38(7A):999-1002. PubMed ID: 3142490
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.